Noble Capital Markets Research Morning Call

Noble Capital Markets Research Report Monday, March 24, 2025

Companies contained in today’s report:

Eledon Pharmaceuticals (ELDN)/OUTPERFORM – All’s Well That Continues Well For Tegoprubart
The GEO Group (GEO)/OUTPERFORM – An Investor Day Full of Opportunity; Raising PT to $35
Xcel Brands (XELB)/OUTPERFORM – Reverse Split Addresses NASDAQ Listing Requirement

Eledon Pharmaceuticals (ELDN/$3.51 | Price Target: $10)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
All’s Well That Continues Well For Tegoprubart
Rating: OUTPERFORM

Eledon Reported 4Q24 Results and Reviewed Progress During The Quarter. Eledon reported a loss for 4Q24 of $44.6 million or $(0.64) per share and $36.2 million or $(0.75) per share for FY2024. Cash and equivalents on December 31, 2024 was $140.2 million, which is expected to fund operations through YE2026. Based on our estimated loss for 1Q25, we project the cash balance on March 31, 2025 to be about $115 million to $120 million.

Tegoprubart Has Clinical Trial Milestones Ahead.  Enrollment in the Phase 2 BESTOW trial for prevention of kidney transplant rejection was completed ahead of schedule in August 2024 due to higher than anticipated interest from transplant surgeons. We anticipate top-line results in 4Q25. The Phase 1b open-label trial continues to evaluate patients and is expected to provide an interim data update in mid-year 2025.

Get the Full Report

The GEO Group (GEO/$28.23 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
An Investor Day Full of Opportunity; Raising PT to $35
Rating: OUTPERFORM

Investor Day. The GEO Group hosted an investor day at the end of last week, during which the Company outlined the substantial growth opportunities available under the new programs to manage undocumented migrants, as well as its goal to both significantly reduce debt and return capital to shareholders.

Secure Facilities. There is an immediate need from ICE for additional detention capacity. This is illustrated by the new contract for GEO’s 1,800 bed North Lake Facility announced last Thursday. This new contract will add $70 million of annualized revenue. Management estimates currently unused bed capacity (including the three facilities recently contracted by ICE) could add $575-$625 million to revenue.

Get the Full Report

Xcel Brands (XELB/$0.32 | Price Target: $17.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Reverse Split Addresses NASDAQ Listing Requirement.
Rating: OUTPERFORM

Reverse split. On March 21, 2025, the company announced a one-for-ten reverse stock split that will take effect at market open on March 25, 2025. Notably, we view the reverse split as a favorable development in the company’s efforts to satisfy NASDAQ’s minimum share price listing requirement of $1. In order to meet NASDAQ’s listing requirement, the XELB shares will need to close above $1 for ten consecutive trading days. Given the current share price of $0.32, we believe the company will likely regain NASDAQ compliance following the reverse split.

Reverse split details. In connection with the reverse split, the company will pay out cash considerations in lieu of issuing fractional shares, and proportionately adjust the underlying common stock and exercise prices of outstanding stock options and warrants. Additionally, the company will continue to trade under the XELB ticker, but will use a new CUSIP number of 98400M200.

Get the Full Report

Noble Capital Markets Research Report Friday, March 21, 2025

Companies contained in today’s report:

Euroseas (ESEA)/OUTPERFORM – EuroHoldings Spin-Off and a New Time Charter Contract
Resources Connection (RGP)/OUTPERFORM – Attractive Risk/Reward

Euroseas (ESEA/$31.22 | Price Target: $51)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
EuroHoldings Spin-Off and a New Time Charter Contract
Rating: OUTPERFORM

New time charter contract. Euroseas executed a new time charter contract for the M/V Rena P, a 4,250 twenty-foot equivalent unit (TEU) intermediate containership. The charter contract is at a gross daily rate of $35,500 for a minimum period of 35 months and a maximum period of 37 months at the charterer’s option. The contract is expected to take effect on August 21, 2025, in continuation of its present charter. The contract is anticipated to contribute roughly $29.0 million in EBITDA during the minimum contract period. The new contract strengthens the company’s charter coverage to 88% in 2025 and 54% in 2026.

Updating estimates. The new charter contract for $35,500 represents a significant improvement compared to the previous rate of $21,000. Consequently, we have increased our 2025 adjusted EBITDA and EPS estimates to $145.1 million and $14.20, respectively, from $139.1 million and $13.35. In addition to the M/V Rena P, our estimates reflect updated time charter contract information for the M/V Marcos, M/V Synergy Antwerp, M/V Synergy Keelung, and M/V EM Hydra.

Get the Full Report

Resources Connection (RGP/$6.85 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Attractive Risk/Reward
Rating: OUTPERFORM

3Q25. With earnings expected on April 2nd, we continue to favor RGP shares. We expect 3Q25 results to remain muted, given the ongoing economic uncertainty and elongated decision times. Nonetheless, we believe RGP’s rich portfolio of diversified offerings encompassing professional staffing support, consulting, and outsourced services creates a strategic powerhouse that we believe will drive value for investors over the long term.

Increased Efficiency in a Growing Market. The global professional services industry is projected to increase by a 6% CAGR over the next five years, growing to $95 billion, according to research published by Statista. With RGP implementing a new technology platform, which will enable increased use of artificial intelligence and automation in the delivery of services as well as back-office operations, we expect the combination of greater revenue and increased efficiency to drive significant results once the economy improves.

Get the Full Report

Noble Capital Markets Research Report Thursday, March 20, 2025

Companies contained in today’s report:

Hemisphere Energy (HMENF)/OUTPERFORM – Strong Cash Flow Supported 2024 Growth and Return of Capital
Tonix Pharmaceuticals (TNXP)/OUTPERFORM – Fourth Quarter Reported As Tonmya PDUFA Approaches

Hemisphere Energy (HMENF/$1.29 | Price Target: $2.35)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Strong Cash Flow Supported 2024 Growth and Return of Capital
Rating: OUTPERFORM

Reserve report. Hemisphere released results from its independent reserve evaluation as of December 31, 2024. Compared to the year-end 2023 reserve report, proved developed producing (PDP) reserves increased 13.1% to 9,302.2 thousand barrels of oil equivalents. The growth in PDP reserves replaced 186% of 2024 production. Hemisphere’s estimated 2024 capital expenditures of ~C$22 million funded PDP reserve growth, annual production growth of ~10%, additional infrastructure, and the testing of a new resource play in Saskatchewan with an enhanced oil recovery (EOR) polymer pilot project.

Outlook for 2025. Hemisphere expects 2025 capital expenditures of ~C$17 million which are expected to support ~15% growth in annual average production to 3,900 barrels of oil equivalent per day (boe/d) compared to 2024. Most of the capital will be allocated to drilling, optimization, and facility work, with ~10% allotted to exploration and land acquisition. The majority of the planned expenditures are scheduled for the third quarter of 2025, providing the company with the flexibility to adjust plans based on changes in commodity prices.

Get the Full Report

Tonix Pharmaceuticals (TNXP/$16.47 | Price Target: $70)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Fourth Quarter Reported As Tonmya PDUFA Approaches
Rating: OUTPERFORM

Fourth Quarter Reported With Product Development Updates. Tonix reported 4Q Net Loss to Common Shareholders of $22.1 million or $(9.77) per share and $130.0 million or $(176.60) per share for FY2024. Total Product sales were $10.1 million with Gross Margin averaging 23% for the full year. The company ended FY2024 with $98.8 million in cash then raised $46.3 million in 1Q25. Including our expected loss for 1Q25, we estimate cash on March 31 to be around $125 million and believe the company has sufficient operating funds into FY2026.

Preparations For Tonmya Are In Progress. Tonix has been assigned a PDUFA date of August 15, 2025, the statutory date for the FDA to answer its NDA for Tonmya (TNX-102 SL). We believe the Phase 3 trials justify approval for fibromyalgia and anticipate broad use for relief of its multiple symptoms. Based on its patient population of over 10 million patients, we believe Tonmya could be a significant revenue generator for Tonix.

Get the Full Report

Noble Capital Markets Research Report Wednesday, March 19, 2025

Companies contained in today’s report:

Bitcoin Depot (BTM)/OUTPERFORM – Poised for a Return Toward Revenue Growth
Conduent (CNDT)/OUTPERFORM – Building Operational Momentum for a Strong 2026
Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – 4Q24 Reported With Hydronidone (F351) Data Coming In 2Q25
Kratos Defense & Security (KTOS)/OUTPERFORM – Some More Business Wins
SKYX Platforms (SKYX)/OUTPERFORM – Pre-Releases Solid Q4 Revenue

Bitcoin Depot (BTM/$1.41 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Poised for a Return Toward Revenue Growth
Rating: OUTPERFORM

Solid Q4 results. The company reported sequential revenue growth in Q4 with revenue of $136.8 million (up from $135.3 million in Q3), better than our estimate of $125.1 million. Adj. EBITDA was $12.0 million, better than our estimate of $6.4 million.

Margin improvement. The strong adj. EBITDA margins of 8.8% in Q4 were the highest of any quarter in 2024. The impressive margins were driven by better transaction spreads at the company’s kiosks, armored transport cost reductions, and lower rents in some kiosk locations. Moreover, the company benefitted from a falloff of initial public company costs (in comparison to the prior year period). 

Get the Full Report

Conduent (CNDT/$2.99 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Building Operational Momentum for a Strong 2026
Rating: OUTPERFORM

2025 preview. We anticipate that the company’s revenue momentum will build throughout the year as new business signings take effect. Moreover, with the prospect of additional efficiencies from initiatives such as corporate-level cost reductions, and a reduction in real estate footprint, we expect adj. EBITDA margins to expand as the year progresses.

Quarterly outlook. In Q1, we expect $767 million in revenue and $14 million in adj. EBITDA, a modest 1.8% margin. However, based on growing revenue and increasing efficiency, we expect adj. EBITDA margins to improve in each subsequent quarter, culminating in margins of nearly 8% in Q4. Given our Q4 revenue estimate of $830 million, we believe the company will exit 2025 with revenue and adj. EBITDA run rates in line with its stated target ($3.2B-$3.3B in annual revenue and 8% adj. EBITDA margins).

Get the Full Report

Gyre Therapeutics, Inc (GYRE/$8.57 | Price Target: $20)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
4Q24 Reported With Hydronidone (F351) Data Coming In 2Q25
Rating: OUTPERFORM

Net Income Was Within Expectations. Gyre Therapeutics reported 4Q24 Net Income Attributable to Common Shareholders of $(0.1) million or $(0.00) per share and FY2024 Net Income of $12.1 million, or $0.14 per basic share and $0.05 per fully diluted share. Revenues were $105.8 million in FY2024 with gross margins of 96.3%, consistent with our revenue estimates of $101.4 million and 96.2% gross margins. As of December 31, 2024, cash on hand was $51.2 million. Separately, results of the Phase 3 clinical trial for Hydronidone will be announced in 2Q25.

Hydronidone Data Announcement Pushed To 2Q25. In its quarterly press release, the company stated that data from the Phase 3 clinical trial for Hydronidone will be announced in 2Q25, although we had expected the data in 1Q25. We do not see this as a significant delay, as it extends the timeframe by 2 to 14 weeks. We believe this can still allow for regulatory filing in China during FY2025.

Get the Full Report

Kratos Defense & Security (KTOS/$31.25 | Price Target: $38)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Some More Business Wins
Rating: OUTPERFORM

Business Wins. Kratos has been awarded a number of new and additions to existing contracts in March. We view these developments positively, although we remain watchful as to the impact of the ongoing continuing resolution for the Federal budget and its implications on new awards in 2025.

BQM-177A Awards. Kratos was awarded $3.4 million from the U.S. Navy for the base year of its next Contractor Logistics Support and Engineering Services contract, supporting BQM-177A aerial target system operations. If all four option years awarded under this contract are exercised, this contract has a potential value of  $19.1 million. The Company also received $59.3 million for an additional 70 BQM-177A Subsonic Aerial Target aircraft through the exercise of the contract option for Full Rate Production (FRP) Lot 6.

Get the Full Report

SKYX Platforms (SKYX/$1.17 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Pre-Releases Solid Q4 Revenue
Rating: OUTPERFORM

Q4 pre-release. On Monday, SKYX pre-released its Q4 revenue results, reporting revenue of $23.7 million (largely aligning with our estimate of $24.0 million). Notably, the company’s revenue grew throughout 2024, from $19.0 million in Q1 to $21.4 million, $22.2 million, and $23.7 million, in the subsequent quarters.

Key leadership additions. The company recently announced the additions of Huey Long as Head of E-commerce and Greg St. John as President of Lighting, Fans and Smart Home Products. Mr. Long previously served as director of e-commerce for Amazon and as an executive at both Ashley Furniture and Walmart. Mr. St. John previously served as head of lighting at Home Depot as well as CEO of EGLO.

Get the Full Report

Noble Capital Markets Research Report Tuesday, March 18, 2025

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – Building on its Pipeline
InPlay Oil (IPOOF)/OUTPERFORM – 2024 Financial Results and 2025 Outlook
Townsquare Media (TSQ)/OUTPERFORM – Attractive Digital Momentum Continues

Bit Digital (BTBT/$2.41 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Building on its Pipeline
Rating: OUTPERFORM

4Q Results. Total revenue for the quarter was $26.1 million, as the HPC business added $14.4 million from last year. We estimated revenue of $29.6 million. Higher G&A and D&A costs partially offset a $43.4 million digital asset gain, resulting in an operating income of $28.8 million. Net income was $29.0 million from $17,700 a year ago. Adjusted EBITDA was $40.1 million from $14.0 million last year.

Pipeline Building Up. Management noted that demand has surged for the B200 GPUs, and with the introduction of DeepSeek, customers are also in demand of the H100 and H200 GPUs. Furthermore, the Company’s data center pipeline has expanded to 510MW from 288MW last quarter. With the increase in demand and management in active discussions with potential customers, we expect more agreements to be announced sooner rather than later.

Get the Full Report

InPlay Oil (IPOOF/$1.12 | Price Target: $3.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
2024 Financial Results and 2025 Outlook
Rating: OUTPERFORM

Full-year 2024 financial results. InPlay Oil reported full-year net income and earnings per share of C$9.5 million and C$0.10, respectively, below our estimates of approximately C$11.4 million and C$0.12. The variance was primarily due to lower-than-expected natural gas revenue driven by weaker AECO pricing. Production for the year averaged 8,712 barrels of oil equivalent per day (boe/d) compared to 9,025 boe/d in 2023. Consequently, revenue decreased to C$153.7 million compared to C$179.4 million in 2023. Adjusted funds flow in 2024 was C$68.5 million, down from C$91.8 million in 2023.

Updated 2025 estimates. Please note that our revised estimates assume the closing of the pending Pembina acquisition on April 15th, 2025. For 2025, our oil and gas revenue estimate is C$333.5 million compared to our prior estimate of C$159.4 million. We have raised our 2025 AFF and EPS estimates to C$161.6 million and C$0.27, respectively, from C$71.7 million and C$0.14. We forecast net income of C$40.9 million, up from our previous estimate of C$13.2 million. Our 2025 estimates are based on an average annual production of 15,879 boe/d compared to our prior forecast of 8,901 boe/d.

Get the Full Report

Townsquare Media (TSQ/$8.14 | Price Target: $21)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Attractive Digital Momentum Continues
Rating: OUTPERFORM

Solid Q4 results. The company reported Q4 revenue of $117.8 million, up 2.6% year over year, and adj. EBITDA of $31.2 million, up 25.8%, both of which were modestly better than our estimates of $115.0 million and $30.4 million, respectively. Notably, the company’s digital businesses were a key revenue growth driver, up a strong 11%.  Digital revenue comprised 52% of total company revenue. Notably, revenue momentum appears favorable into the second quarter. 

Digital leads the way. Total digital revenue growth of 11% was comprised of digital advertising growth of 15% and a swing toward revenue growth in its subscription digital marketing solutions (DMS) of 1.9%. DMS returned to revenue growth for the first time since Q4 of 2022. Second quarter digital revenue continues to be strong, expected to increase a solid 7.3% in Q2. 

Get the Full Report

Noble Capital Markets Research Report Monday, March 17, 2025

Companies contained in today’s report:

E.W. Scripps (SSP)/OUTPERFORM – Heightened M&A Environment and Debt Reduction Should Drive Stock Valuation
FreightCar America (RAIL)/OUTPERFORM – Thoughts on RAIL’s Recent Shelf Registration
Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Announces $50 Million Share Buyback

E.W. Scripps (SSP/$2.64 | Price Target: $10)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Heightened M&A Environment and Debt Reduction Should Drive Stock Valuation
Rating: OUTPERFORM

Solid Q4 Results. Revenue increased a strong 18.3% to $728.4 million, beating our $716.1 million estimate. The results benefited from better core advertising ($147.4 million vs our $143.0 million est.) and higher Political revenue ($174.4 million vs our $172.0 million est.). Adj. EBITDA was $229.6 million, better than our $226.1 million estimate.

Cost efficiency focused. The company highlighted that it is on track to deliver improved margins in its Scripps Networks division by 400 to 600 basis points in 2025. Furthermore, we anticipate the cost reductions will largely be driven by reduced headcount, followed by more modest reductions in program license costs and other expenses.

Get the Full Report

FreightCar America (RAIL/$6.58 | Price Target: $13.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Thoughts on RAIL’s Recent Shelf Registration
Rating: OUTPERFORM

Shelf registration. FreightCar recently filed a universal shelf registration statement pertaining to the offer and sale from time to time of up to $200 million in aggregate of the company’s common stock, preferred stock, debt securities, new warrants, rights or units, and the resale by a selling stockholder, affiliates of PIMCO, of up to 17,038,583 shares of common stock. PIMCO has now registered the shares associated with its warrants which enables them to sell shares over time following the exercise of the warrants. The warrants are already reflected in RAIL’s fully diluted share count and in our financial model.

Cleaner financial reporting. The change in the fair market value of the warrant liability fluctuates each quarter in line with the change in RAIL’s stock price during the period. The valuation adjustment reflects accounting for the warrant holder’s investment. For the full year 2024, the company recognized a $99.5 million non-cash adjustment due to the change in the fair market value of the warrant liability. All shares underlying the warrants have been reflected as part of the weighted shares outstanding since their issuance in prior years. Eliminating the warrant liability and need to report on the change in its fair market value could narrow the difference between GAAP and adjusted earnings.

Get the Full Report

Great Lakes Dredge & Dock (GLDD/$8.65 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Announces $50 Million Share Buyback
Rating: OUTPERFORM

New Buyback Program. On Friday, Great Lakes Dredge & Dock Corporation announced that its Board of Directors has authorized a share repurchase program pursuant to which the Company may repurchase up to $50 million of its common stock. At the current price, the $50 million equates to 5.78 million GLDD shares or approximately 8.6% of the outstanding common. The share repurchase program expires on March 14, 2026.

Rationale. According to management, “Our business is strong, as we delivered in 2024 the second best results in our Company’s history. The outlook for 2025 and 2026 is also strong, with $1.2 billion in backlog as of December 31, 2024. Our new build program is also expected to be substantially completed in 2025. We believe the Company’s current share price does not reflect the strength of our business and that a share repurchase program will be accretive to our shareholders.” 

Get the Full Report

Noble Capital Markets Research Report Friday, March 14, 2025

Companies contained in today’s report:

Cadrenal Therapeutics (CVKD)/OUTPERFORM – FY2024 Report Reviews A Pivotal Year For Tecarfarin
Comtech Telecommunications (CMTL)/MARKET PERFORM – Making Progress
FreightCar America (RAIL)/OUTPERFORM – Solid 2024 Financial and Operating Performance; Updating Estimates
Zomedica (ZOM)/OUTPERFORM – Sales Growth Continued In FY2024; Stock Price Discussed

Cadrenal Therapeutics (CVKD/$17.45 | Price Target: $45)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
FY2024 Report Reviews A Pivotal Year For Tecarfarin
Rating: OUTPERFORM

FY2024 Was A Productive Year. Cadrenal reported a 4Q24 loss of $4.2 million or $(2.55) per share and FY2024 loss of $10.7 million or $(8.73) per share. An important development discussed in our Research Note on March 5 was Cadrenal’s announcement of a collaborative agreement with Abbott (ABT, Not Rated) for support of its pivotal trial testing tecarfarin in patients with left ventricular assist (LVAD) devices. Cash and equivalents on December 31 were $10.0 million.

Tecarfarin Is In Development For Several Patient Populations With Coagulation Needs. Many patients that are at risk for cardiovascular events (stroke, embolism, deep vein thrombosis) take anticoagulants in the direct oral anticoagulant class (DOACs, such as Eliquis or Xarelto). However, there are several patient populations that must take warfarin, an older drug, due to lack of efficacy or high bleeding risk. Tecarfarin is being developed to replace warfarin in these populations. Cadrenal has Orphan Drug designation from the FDA for implanted mechanical devices (LVADs) and prevention of systemic thromboembolism in end-stage kidney disease (ESKD) and atrial fibrillation (AFib).

Get the Full Report

Comtech Telecommunications (CMTL/$1.89)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Making Progress
Rating: MARKET PERFORM

Making Progress. Comtech made some progress in its business transformation during the fiscal second quarter, although business conditions remain challenging. The most significant change came post quarter-end with the amendment to its senior secured credit agreement that cures the covenant breaches as of January 31, 2025.

2Q25 Results. Revenue totaled $126.6 million, down 5.7% from the year ago period, but up 9.3% sequentially. Gross margin of 26.7% fell y-o-y, but improved sequentially from 12.5% in 1Q25. Comtech reported a net loss of $48.7 million, before preferred stock adjustments, compared to a net loss of $10.6 million in 2Q24. Adjusted net loss was $0.35/sh compared to a net loss of $0.15/sh last year.

Get the Full Report

FreightCar America (RAIL/$7.32 | Price Target: $13.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Solid 2024 Financial and Operating Performance; Updating Estimates
Rating: OUTPERFORM

Full year 2024 financial results. FreightCar America generated 2024 adjusted net income to common stockholders of $4.4 million or $0.15 per share compared to a loss of $11.0 million or $(0.39) per share in 2023 and our estimate of $5.5 million or $0.17 per share. Gross margin as a percentage of revenue increased to 12.0% compared to 11.7% in FY 2023. Revenue and rail car deliveries increased to $559.4 million and 4,362 compared to $358.1 million and 3,022 in 2023. We had forecast revenue of $577.4 million and deliveries of 4,550. Adjusted EBITDA increased to $43.0 million compared to $20.1 million in 2023 and our estimate of $38.3 million. Full year adjusted free cash flow amounted to $21.7 million versus $(17.6) million in 2023.

Full Year 2025 corporate guidance. Management issued full year 2025 guidance. Railcar deliveries are expected to be in the range of 4,500 to 4,900, revenue is expected to be in the range of $530 million to $595 million, and adjusted EBITDA is expected to be in the range of $43 to $49 million. Compared to 2024, railcar deliveries, revenue, and adjusted EBITDA are expected to increase 7.7%, 0.6%, and 7.0%, respectively, at the midpoints of guidance.

Get the Full Report

Zomedica (ZOM/$0.04 | Price Target: $0.25)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Sales Growth Continued In FY2024; Stock Price Discussed
Rating: OUTPERFORM

Product Sales Drove Revenue Growth. Zomedica reported 4Q24 revenues of $7.9 million and FY2024 revenues $27.3 million, in line with our estimates of $8.0 million and $27.5 million. Gross Margins were 70.0% as expected, with a loss for FY2024 of $46.9 million or $(0.05) per share. Cash and equivalents on December 31 was $71.4 million.

CEO Addressed Recent Stock Delisting. At the beginning of the quarterly conference call, CEO Larry Heaton spoke about the events leading to the delisting from the New York American Exchange earlier this month. As discussed in our Research Note on March 11, the recent market weakness brought the stock below the threshold for continued listing. This weakness led to a move to the OTCQB Venture Market, causing further weakness.

Get the Full Report

Noble Capital Markets Research Report Thursday, March 13, 2025

Companies contained in today’s report:

FreightCar America (RAIL)/OUTPERFORM – FreightCar Provides Outlook for 2025; Investor Webinar at 11:00 AM ET

FreightCar America (RAIL/$6.23 | Price Target: $13.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
FreightCar Provides Outlook for 2025; Investor Webinar at 11:00 AM ET
Rating: OUTPERFORM

Full year 2024 financial results. FreightCar America generated 2024 adjusted net income to common stockholders of $4.5 million or $0.15 per share compared to a loss of $11.0 million or $(0.39) per share in 2023 and our estimate of $5.5 million or $0.17 per share. Gross margin as a percentage of revenue increased to 12.0% compared to 11.7% in FY 2023. Revenue and rail car deliveries increased to $559.4 million and 4,362 compared to $358.1 million and 3,022 in 2023. We had forecast revenue of $577.4 million and deliveries of 4,550. Adjusted EBITDA increased to $43.0 million compared to $20.1 million in 2023 and our estimate of $38.3 million. Full year adjusted free cash flow amounted to $21.7 million versus $(17.6) million in 2023.

Full Year 2025 corporate guidance. Management issued full year 2025 guidance. Railcar deliveries are expected to be in the range of 4,500 to 4,900, revenue is expected to be in the range of $530 million to $595 million, and adjusted EBITDA is expected to be in the range of $43 to $49 million. Compared to 2024, railcar deliveries, revenue, and adjusted EBITDA are expected to increase 7.7%, 0.6%, and 7.0%, respectively, at the midpoints of guidance. Our current 2025 estimates include railcar deliveries of 4,675 units, revenue of $580.6 million and EBITDA of $44.9 million.

Get the Full Report

Noble Capital Markets Research Report Wednesday, March 12, 2025

Companies contained in today’s report:

Commercial Vehicle Group (CVGI)/OUTPERFORM – Tough End to a Challenging Year
E.W. Scripps (SSP)/OUTPERFORM – Takes Steps To Assuage Debt Concerns
Saga Communications (SGA)/OUTPERFORM – Digital Growth Strategy Appears To Be Gaining Traction

Commercial Vehicle Group (CVGI/$1.79 | Price Target: $4)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Tough End to a Challenging Year
Rating: OUTPERFORM

4Q Results. CVG reported 4Q24 revenue of $163.3 million, down 15.7% y-o-y due to ongoing weakness in the Construction and Ag markets, as well as a drop in Class 8 truck builds. Adjusted EBITDA was $0.9 million, down from $8.3 million. CVG reported an adjusted loss from continuing operations of $5.1 million, or a loss of $0.15/sh, compared to adjusted net income of $2.1 million, or EPS of $0.06, in 4Q23.

Strategic Initiatives. The Company implemented a number of strategic initiatives during 2024, including portfolio rationalization and the elimination of some 1,300 positions. These should result in some $15 million of gross savings in 2025, which should help improve margins.

Get the Full Report

E.W. Scripps (SSP/$1.43 | Price Target: $10)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Takes Steps To Assuage Debt Concerns
Rating: OUTPERFORM

Q4 results exceed expectations. Revenues increased a strong 18.3% to $728.4 million, beating our $716.1 million estimate. The results benefited from better core advertising ($147.4 million vs our $143.0 million est.) and higher Political revenue ($174.4 million vs our $172.0 million est.). Adj. EBITDA was $229.6 million, better than our $226.1 million estimate. Figure #1 Q4 Results highlight our estimates versus reported results. 

Sluggish start. Management provided lackluster Q1 revenue guidance, expecting Local Media revenue to be down high single- digits with Scripps Networks revenue to be down mid single-digits. The sluggish Q1 reflects the absence of Political revenue, but likely weak core spot and National spot advertising. Notably, management guided interest expense to be $175 million to $185 million, less than our estimate of roughly $200 million. 

Get the Full Report

Saga Communications (SGA/$12.11 | Price Target: $24)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Digital Growth Strategy Appears To Be Gaining Traction
Rating: OUTPERFORM

An in-line quarter. The company reported Q4 revenue of $28.8 million and adj. EBITDA of $3.1 million, both of which declined over the prior year period, but were modestly better than our estimates of $27.7 million and $2.3 million, respectively. Notably, the company is focused on its blended digital growth strategy and reducing costs and improving profitability. We believe the company’s strategic actions are a step in the right direction for returning toward revenue and adj. EBITDA growth.

Cost-effective digital growth strategy. A key focus of the company is reducing costs that have no impact on revenue and continuing to emphasize the roll out of its blended digital advertising strategy. Notably, the blended strategy combines radio and digital advertising to provide a consistent message to customers on both mediums and to drive radio listeners to digital platforms. We view the company’s emphasis on the unique strategy favorably.

Get the Full Report

Noble Capital Markets Research Report Tuesday, March 11, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Updating Estimates to Reflect AVAIL Transaction
Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – Initiation of Coverage: Focused On Fibrosis
Zomedica (ZOM)/OUTPERFORM – Fundamentals Have Been Improving, But Price Weakness Leads To Delisting

AZZ (AZZ/$87.73 | Price Target: $112)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Updating Estimates to Reflect AVAIL Transaction
Rating: OUTPERFORM

AVAIL joint venture. Through a joint venture, AZZ owns a non-controlling 40% interest in Avail Infrastructure Solutions with the remaining 60% owned by the Fernweh Group LLC. Avail recently executed a definitive agreement to sell its Electrical Products Group to nVent Electric plc (NYSE: NVT) for $975 million, subject to adjustments. The transaction is expected to close during the first half of the 2025 calendar year. AZZ will continue to own a 40% interest in Avail which will consist of its Industrial Lighting and Welding Solutions businesses.

Use of proceeds. AZZ will use its share of the transaction proceeds to further reduce debt or fund potential M&A activity. The gain on the transaction will be treated as a one-time adjustment to net income and EPS. A reduction in the $16 million to $18 million of joint venture equity income included in AZZ’s fiscal year 2026 guidance is expected to be offset by interest savings. While AZZ is not adjusting its fiscal year 2026 earnings guidance, debt reduction will be higher than the range of $140 million to $160 million provided in their guidance.

Get the Full Report

Gyre Therapeutics, Inc (GYRE/$10.33 | Price Target: $20)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Initiation of Coverage: Focused On Fibrosis
Rating: OUTPERFORM

We Are Initiating Coverage Of Gyre Therapeutics With An Outperform Rating. Gyre Therapeutics is a pharmaceutical company developing drugs for inflammatory diseases that lead to fibrosis. It currently markets Etuary (pirfenidone) in China for idiopathic pulmonary fibrosis. The lead drug in the pipeline is Hydronidone, a new molecule derived from pirfenidone, that is in a Phase 3 clinical trial in China. The data announcement is expected to report Phase 3 clinical trial results in March 2025.

Hydronidone Was Developed To Improve Efficacy and Side Effects. Hydronidone is a structural analogue of pirfenidone that was developed to improve efficacy with a more tolerable side effect profile. It is in Phase 3 trial in China for fibrosis of the liver after hepatitis B (HBV) infections. Hydronidone targets steps in the Transforming Growth Factor (TGF)-ß1 pathway as well as the downstream genes and liver cells it activates to produce fibrotic tissue. Data from the Phase 3 in China will be used to design a Phase 2a trial in the US, expected to begin in late FY2025.

Get the Full Report

Zomedica (ZOM/$0.1 | Price Target: $0.25)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Fundamentals Have Been Improving, But Price Weakness Leads To Delisting
Rating: OUTPERFORM

Recent Price Weakness Forces Move To The OTC Bulletin Board. As the recent decline in the overall markets was affecting companies in many sectors, the closing price of Zomedica stock fell below $0.10 per share on March 3. This crossed a threshold set by the New York American exchange, forcing the delisting of ZOM shares. Zomedica shares began trading on the OTCQB Venture Market under the symbol ZOMDF. There were no other events or crisis that caused the delisting.

During 2024, Zomedica Has Met All Of The Product Goals We Expected. Over the past year, Zomedica has introduced several new assays for use with its TRUFORMA diagnostics platform. These assays are sold to veterinary practices for use with TRUFORMA diagnostic instruments, allowing the veterinarian to run tests without sending samples to an outside lab. This allows the diagnosis in a few minutes and allows the practice to capture the profit from the tests. The TRUFORMA assays, reported as diagnostic consumables, have been one of the sources of sales growth over the past year.

Get the Full Report

Noble Capital Markets Research Report Monday, March 10, 2025

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – Full Year 2024 Review and Outlook
Direct Digital Holdings (DRCT)/MARKET PERFORM – Diversifying Revenue Sources
Information Services Group (III)/OUTPERFORM – Noticing Positive Trends in 2025
The ODP Corporation (ODP)/OUTPERFORM – New Partnership

Comstock (LODE/$2.59)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Full Year 2024 Review and Outlook
Rating: MARKET PERFORM

Investor webinar. On March 6, Comstock hosted a webinar to discuss the company’s full year 2024 results and provided a comprehensive business update. Management highlighted significant accomplishments achieved in 2024 and its plans for 2025.

Upcoming events. While Comstock summarized corporate and subsidiary-level objectives for 2025, we view several as significant. These include: 1) Comstock Fuels’ completion of offtake, joint development, and warrant agreements with Marathon Petroleum Corporation on or before June 30, 2025, 2) completion of a Comstock Fuels Series A financing during the second quarter, 3) construction of Comstock Metals’ first large-scale recycling facility at a cost of $6 million, 4) advancement of project level financing for subsidiary projects, and 5) the sale of Comstock’s properties and water rights in Silver Springs, Nevada in the latter part of 2025.

Get the Full Report

Direct Digital Holdings (DRCT/$0.9)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Diversifying Revenue Sources
Rating: MARKET PERFORM

Focus on rebuilding revenue. Over the past several months, the company has been focused on diversifying its revenue streams as it rebuilds revenue. Prior to Q3, the company’s largest sell-side customer accounted for roughly 80% of the segment’s revenue. After the large client reduced volume, negatively impacting Q3 results, the company is focused on not letting any one client comprise more than 20% – 30% of revenue.

New joint venture. On March 5, the company announced a new joint venture, Teranexa, with Green Tea Technology. This venture is focused on utilizing AI to improve efficiencies in small and medium-sized cities. Notably, Teranexa will combine the company’s data monetization expertise with Green Tea’s experience in IT project deployment, leveraging its partner network of IBM and HPE.

Get the Full Report

Information Services Group (III/$3.3 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Noticing Positive Trends in 2025
Rating: OUTPERFORM

Improved Metrics. While fourth quarter revenue was down on a reported basis, it was in-line with our expectations and at the upper-end of management’s $57-$58 million guidance. Importantly, ISG delivered an improved gross margin of 41.5% from 38.3% last year due to higher utilization and the sale of its automation unit. Flowing through to the bottom line, adjusted EBITDA had an improved margin of 11.3% from 8.9% last year.

A Year of Headwinds. Fiscal year 2024 was highlighted by headwinds for the Company, as its clients delayed decision making throughout the year. Uncertainty regarding the macroenvironment, geopolitical conflict in Europe, and political uncertainty impacted spending in 2024.

Get the Full Report

The ODP Corporation (ODP/$16.61 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
New Partnership
Rating: OUTPERFORM

New Partnership. The ODP Corporation continued its B2B push with the signing of a new partnership agreement with CoreTrust. The agreement marks the latest in a series of new contracts for ODP Business Solutions, moving the segment into new, growing industries. Through this partnership, ODP Business Solutions will offer products and services to CoreTrust’s 3,500+ business member purchasing collective, which serves major industries including retail, manufacturing, hospitality, and finance.

Details. Under the contract, ODP Business Solutions will supply CoreTrust members with high-quality solutions, including interiors/furniture, technology, breakroom supplies, and paint, promotion, and apparel services at an exceptional value. These categories are expected to expand industry wide by a 4-6% compound annual growth rate over the next five years.

Get the Full Report

Noble Capital Markets Research Report Friday, March 7, 2025

Companies contained in today’s report:

Information Services Group (III)/OUTPERFORM – A Peak into the Fourth Quarter
NN (NNBR)/OUTPERFORM – Transformation Taking Effect
Seanergy Maritime (SHIP)/OUTPERFORM – Record Profitability in 2024; Updating 2025 Estimates

Information Services Group (III/$3.1 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A Peak into the Fourth Quarter
Rating: OUTPERFORM

Fourth Quarter Results. Revenue for the quarter totaled $57.8 million, nearing the top of management’s guidance and in-line with our estimate of $58 million. Net income totaled $3.0 million, or $0.06 per diluted share, an improvement from a loss of $2.9 million or $0.06 per share, last year. We estimated a net loss of $0.2 million or breakeven per share. Adjusted EBITDA was $6.5 million, the midpoint of management’s guidance and above our estimate of $6 million.

More Cash in Hand. ISG generated cash from operations of $6.6 million during the quarter, and with the sale of the automation unit last quarter, had total cash on hand of $23.1 million at the end of the quarter, up 138% from the prior quarter. Debt declined to 25% y-o-y to $59.2 million as of December 31, 2024. Management maintained a goal of 2.0-2.5x debt to EBITDA ratio.

Get the Full Report

NN (NNBR/$2.59 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Transformation Taking Effect
Rating: OUTPERFORM

Remain on Track. The first full year of NN’s transformation produced significant results, although the improvements were somewhat obscured in the GAAP reported results. With the successful change in the business trajectory, NN remains on track to achieve its 2028 financial goals of $650 million of net sales, with an adjusted EBITDA margin in the 12-13% range.

More Transformation in 2025. Management is not resting on its laurels. 2025 will continue the transformation plan with specific emphasis on improving or eliminating underperforming business, additional costs out, new business wins, and balance sheet improvement through a debt refinance.

Get the Full Report

Seanergy Maritime (SHIP/$7.07 | Price Target: $13)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Record Profitability in 2024; Updating 2025 Estimates
Rating: OUTPERFORM

Fourth quarter financial results. Seanergy Maritime reported fourth quarter adjusted EBITDA and earnings per share (EPS) of $20.4 million and $0.34, respectively, exceeding our estimates of $19.3 million and $0.27. Revenue was modestly above our estimate due to better-than-expected available operating days, while expenses were marginally lower-than-expected, driven by operational efficiencies for voyage and vessel expenses. Operating income was $10.7 million compared to our estimate of $10.1 million.

2025 market outlook. Capesize rates fell in early 2025 due to an increase in the effective supply of vessels caused by low congestion in ports and smaller vessels taking on cargo typically reserved for the Capesize fleet. However, Capesize market rates have since rebounded and are expected to stay relatively steady throughout 2025. Limited new vessel orders and deliveries, increasing environmental regulations, and rising iron ore and bauxite exports are supporting Cape vessel rates amid a broader downturn in the dry-bulk market.

Get the Full Report

Noble Capital Markets Research Report Thursday, March 6, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Updating Estimates; Raising PT
CoreCivic, Inc. (CXW)/OUTPERFORM – South Texas to Resume Operations
FAT Brands (FAT)/OUTPERFORM – Post Call Commentary
NN (NNBR)/OUTPERFORM – A Look into the Fourth Quarter
Ocugen (OCGN)/OUTPERFORM – Ocugen Reports FY2024 With Progress Toward “3 BLA Filings In 3 Years”

AZZ (AZZ/$90.03 | Price Target: $112)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Updating Estimates; Raising PT
Rating: OUTPERFORM

A market leader with a strong growth profile. AZZ is the leading independent provider of hot dip galvanizing and coil coating solutions to a broad range of end markets. We expect AZZ Precoat Metals’ new manufacturing facility in Washington, Missouri to contribute to top-line growth in fiscal year 2026 while capital expenditures decline. Approximately 75% of the facility’s production is already committed and could generate $50 million to $60 million in revenue on an annualized basis once production is fully ramped. 

Fiscal 2026 corporate guidance. In early February, AZZ Inc. released financial guidance for fiscal year 2026 and expects sales in the range of $1.625 billion to $1.725 billion, adjusted EBITDA in the range of $360 million to $400 million, and adjusted diluted EPS of $5.50 to $6.10. Fiscal year 2026 guidance included an increase in the Metal Coatings EBITDA margin expectations to a range of 27% to 32% from 25% to 30%, while Precoat Metals EBITDA margin expectations are unchanged at 17% to 22%.

Get the Full Report

CoreCivic, Inc. (CXW/$18.4 | Price Target: $25)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
South Texas to Resume Operations
Rating: OUTPERFORM

South Texas to Resume. Yesterday, CoreCivic announced a new intergovernmental agreement to resume operations at the 2,400-bed South Texas Family Residential Center in Dilley, Texas, for ICE. CoreCivic has entered into a new lease agreement with Target Hospitality, the owner of the facility, over period concurrent with the ICE agreement. We view this a further confirmation of the Federal government’s need for additional bed capacity in the drive to deport undocumented migrants.

Details. The amended IGSA expires in March 2030 and may be further extended through bilateral modification. The agreement provides for a fixed monthly payment in accordance with a graduated schedule to correlate with the activation of each neighborhood within the facility. Once fully activated, total annual revenue is expected to be approximately $180 million, including medical services. With the Company having already started pre-activation activities earlier this year, we expect this award to be accretive to earnings beginning in the second quarter of 2025.

Get the Full Report

FAT Brands (FAT/$3.15 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Post Call Commentary
Rating: OUTPERFORM

Twin Hospitality. Significant opportunity remains at Twin Hospitality. The Company ended the year with 115 Twin Peaks lodges, having opened nine new lodges. Twin Hospitality expects to open an additional 9-11 lodges in 2025, with 6-7 franchised and an additional 10-15 lodges in both 2026 and 2027. The Company has over 100 signed franchised commitments and the remaining conversion of approximately 30 Smokey Bones locations to drive new openings.

New Openings. FAT Brands expects to open over 100 new locations in 2025, with 17 already opened year-to-date. We anticipate strong organic growth across the portfolio in 2025. The current development pipeline consists of signed agreements for approximately 1,000 additional locations, including over 250 units signed in 2024. Once these units are opened, we expect them to generate approximately $50 million in incremental annual adjusted EBITDA.

Get the Full Report

NN (NNBR/$2.7 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A Look into the Fourth Quarter
Rating: OUTPERFORM

Year of Transformation. Management highlighted its first full year of transformation, as the Company upgraded leadership positions and added to its Stamped Products, Electrical, and Medical teams. They also secured new business to offset rationalized business and create a path to y-o-y growth, increased gross margins, and decreased leverage to name a few actions. Lastly, the underperforming plants are expected to generate positive EBITDA in the new year compared to a negative $11.5 million last year.

New Business Wins. The Company had $73 million of new business wins for the fiscal year, surpassing the previous year of $63 million. As for 2025, the Company has $13 million in new wins year-to-date and remains on pace towards its guidance of $60-$70 million in new wins for the year. These wins are expected to soon ramp into Company sales as well, with roughly $21 million of new business expected to launch in Q1 2025 across multiple plants and countries.

Get the Full Report

Ocugen (OCGN/$0.57 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Ocugen Reports FY2024 With Progress Toward “3 BLA Filings In 3 Years”
Rating: OUTPERFORM

Clinical Progress Expected To Lead To Filings For Three Product Approvals. Ocugen reported a 4Q24 loss of $13.9 million or $(0.05) per share and FY2024 loss of $54.1 million or $(0.20) per share. The company made significant progress in its clinical trials during the quarter and since the start of FY2025. It has also received regulatory designations that accelerate product approval. The company had $58.5 million in cash on December 31, sufficient to fund operations through 1Q26.

Clinical Trial Advances Point To Three BLAs In 3 Years. Ocugen has made significant progress with three products for three diseases that lead to vision loss. The three ongoing trials are Phase 3 for OCU400, the Phase 2/3 for OCU410ST in Stargardt disease, and the Phase 1/2 trial for GA. These trials are on schedule for filing applications for approval in 2026, 2027, and 2028 respectively. OCU400 and OCU410ST have Orphan Drug designations that can accelerate approval, while GA is a large market of over 10 million patients in the US alone.

Get the Full Report

Noble Capital Markets Research Report Wednesday, March 5, 2025

Companies contained in today’s report:

Cadrenal Therapeutics (CVKD)/OUTPERFORM – Development Agreement With Abbott Brings Another Tecarfarin Indication To Clinical Trials
The GEO Group (GEO)/OUTPERFORM – Upgrading to Outperform with $32 PT

Cadrenal Therapeutics (CVKD/$17.57 | Price Target: $45)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Development Agreement With Abbott Brings Another Tecarfarin Indication To Clinical Trials
Rating: OUTPERFORM

Cadrenal and Abbott Announce The LVAD Collaboration We’ve Been Waiting For. Cadrenal announced a development agreement with Abbott (ABT, Not Rated) to develop Tecarfarin in patients with Abbott’s HeartMate3 LVAD (left ventricle assist device). Under the agreement, Abbott will support Cadrenal’s pivotal TECH-VLAD (TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices) trial in its design, site selection, recruitment, and its HeartMate3 experience.

LVAD Patients Have An Unmet Need For A New Anticoagulant. While Direct Oral Anticoagulation Drug (DOAC) category has been highly successful, there are several populations where they are not effective or have safety risks. Patients with LVAD devices can only use warfarin, a drug that has variable efficacy with several drawbacks, including a requirement for frequent patient monitoring. LVAD patients have less effective anticoagulation and remain at high risk for coagulation events (bleeding, stroke, myocardial infarct). 

Get the Full Report

The GEO Group (GEO/$25.9 | Price Target: $32)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Upgrading to Outperform with $32 PT
Rating: OUTPERFORM

Upgrading to Outperform. We are upgrading GEO shares to Outperform with a $32 near-term price target. We believe there is substantial opportunity just in filling existing beds under current contracts, with the opening of currently idle facilities, new facilities, and expansion of the ISAP program providing additional upside.

Opportunity. GEO has an additional 17,000 beds to provide for ICE detention requirements, which would increase GEO’s overall bed capacity for ICE to about 32,000 beds. The incremental 17,000 beds includes approximately 9,400 beds in current idle facilities that will be reconfigured for detention use and approximately 7,700 incremental beds available at existing GEO serviced ICE and U.S. Marshal’s facilities under contract. Management estimates the utilization of these additional 17,000 beds could generate between $500 million and $600 million in incremental annualized revenues, with margins consistent with secure services owned facilities which average 25% to 30%.

Get the Full Report

Noble Capital Markets Research Report Tuesday, March 4, 2025

Companies contained in today’s report:

Ocugen (OCGN)/OUTPERFORM – OCU410 and OCU410ST Receive ATMP Classification in Europe
The ODP Corporation (ODP)/OUTPERFORM – Doubling Down on B2B
Comtech Telecommunications (CMTL)/MARKET PERFORM – Some Breathing Space

Ocugen (OCGN/$0.61 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
OCU410 and OCU410ST Receive ATMP Classification In Europe
Rating: OUTPERFORM

Ocugen Now Has Three Products With ATMP Designation. Two Ocugen products, OCU410 and OCU410ST, received Advanced Therapy Medicinal Product (ATMP) designation from the European Medicines Agency Committee for Advanced Therapies (EMA-CAT). These join OCU400, which received this designation for retinitis pigmentosa (RP) in February 2025. The designation is similar to the Breakthrough Therapy designation from the FDA, allowing increased interactions with the regulators and accelerating regulatory review.

OCU410 Has Completed Phase 2 Dosing In GA. The Phase 2 portion of the ArMaDa (pronounced ‘Armada”) trial has completed enrollment for OCU410 in geographic atrophy (GA), a lesion that results from advancing dry Age-related Macular Degeneration (dry AMD). The study has enrolled 51 patients randomized into a high dose arm, medium dose arm, or control. The completion of the dosing phase was ahead of our expected time frame, keeping the company on schedule to conduct Phase 3 in 2026 and potentially file for regulatory approval in 2028.

Get the Full Report

The ODP Corporation (ODP/$14.42 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Doubling Down on B2B
Rating: OUTPERFORM

Macro Headwinds. While macro headwinds remain in the B2B and B2C segments, green shoots are appearing, with new B2B contracts and an expanding pipeline of new business opportunities. Over at retail, the Company has seen improved traction with targeted profitable sales campaigns and value added promotions.

Playing to its Strengths. Project “Optimize for Growth” and the B2B focus plays into ODP’s core strengths, such as robust supply chain assets, distribution capabilities, and an expansive B2B customer base. We believe these moves position ODP to unlock sustainable growth and long-term success.

Get the Full Report

Comtech Telecommunications (CMTL/$1.61)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Some Breathing Space
Rating: MARKET PERFORM

New Capital Infusion. Last night, after the market closed, Comtech Telecommunications announced a new $40 million capital infusion from the current holders of Comtech’s convertible preferred and subordinated debt, or White Hat Capital and Magnetar Financial. The new capital infusion is made on the same terms and conditions as the prior subordinated debt investment.

Uses. Of the $40 million infusion, $27.3 million is being used to prepay the senior secured term loan and $3.2 million to reduce the revolving credit facility, with a waiver of the prepayment penalties that would have been owed in accordance with the terms of the credit agreement.

Get the Full Report

Noble Capital Markets Research Report Monday, March 3, 2025

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – Strategic Partnership with Marathon Petroleum
Euroseas (ESEA)/OUTPERFORM – Fourth Quarter and FY 2024 Review and Outlook

Comstock (LODE/$2.4)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Strategic Partnership with Marathon Petroleum
Rating: MARKET PERFORM

Marathon investment in Comstock Fuels. Comstock Fuels entered into definitive agreements with subsidiaries of Marathon Petroleum Corporation, including the purchase of $14.0 million in Comstock Fuels equity as part of Comstock’s planned Series A preferred equity financing. Consideration includes $13.0 million in payment-in-kind (PIK) assets comprised of equipment, intellectual property, and other materials at Marathon’s former renewable fuel demonstration facility in Madison, WI. While the PIK assets were transferred as of the February 28 effective date, the cash portion will be received within five business days of Comstock Fuels’ execution of third-party Series A financing agreements totaling at least $25.0 million.

Key elements of the agreements. The agreements included: 1) an agreement for future equity governing the portion of the investment issued in exchange for the PIK assets, 2) an asset transfer agreement to assign the PIK assets, 3) a license agreement covering applicable intellectual property, 4) an agreement to provide post-closing conditions, and 5) a board observer agreement executed as of the effective date. Separately, Comstock executed a commercial lease for the Madison facility at a rate of $44,000 per month.

Get the Full Report

Euroseas (ESEA/$35.4 | Price Target: $51)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Fourth Quarter and FY 2024 Review and Outlook
Rating: OUTPERFORM

Fourth quarter results. Euroseas reported fourth quarter 2024 adjusted EBITDA and earnings per share (EPS) of $32.8 million and $3.33, respectively, compared to our estimates of $34.7 million and $3.66. While revenues were generally in line with our estimates, operating expenses were higher than expected. Drydocking expenses were ~$1.7 million above our estimates, while general and administrative expenses were ~$600 thousand above our estimates due to higher share-based compensation.

2025 outlook. Container ship charter rates remained stable in the fourth quarter, with feeder and intermediate segments showing modest gains in early 2025. While ongoing disruptions in the Red Sea continue to support rates, the potential reopening of the Suez Canal could have a negative impact. The global containership orderbook remains high, and vessels have started to come to market. While a large orderbook poses risks, the feeder and intermediate sectors where Euroseas operates face limited new supply and aging fleets.

Get the Full Report

Noble Capital Markets 2025 Virtual Conference

Noble Capital Markets’ Emerging Growth Virtual Equity Conference – June 4-5, 2025

Set to be an immersive experience, bringing together investors, industry leaders, and experts from middle market public companies across all sectors. Featuring:

Corporate presentations with Fireside-style Q&A session proctored by Noble’s analysts and bankers

Scheduled 1×1 meetings with qualified investors

More than 50 presenting companies, representing a wide array of sectors.

Why Present?

Noble’s investor base extends beyond traditional institutions to include family offices, money managers, and high-net-worth individuals who actively engage in smaller cap, open market transactions.

Noble’s investors crave the undervalued investment idea.

And not just investors that attend the live event. Channelchek will host replays of the corporate presentations and Q&A sessions right here, for all investors to view, free of charge, for the rest of the year.

Participation in conferences, both in-person and virtually, has proven to help in boosting awareness and liquidity. And Noble’s service offerings extend well beyond the conference circuit; our events are an extension of the year-round investor access we provide.

***Investor / Attendee registration will open in the spring***

Ready to Register to Present? Click the link below:

Have questions about registering to present?

Email: Noble’s Conference Team

Learn more about Noble’s Investor Events throughout the year:

Noble Capital Markets Investor Events

Alumis and ACELYRIN Announce Definitive Merger Agreement in All-Stock Transaction

Key Points:
– Alumis and ACELYRIN have agreed to an all-stock merger, creating a well-capitalized biopharmaceutical company focused on advancing immunology treatments.
– The combined company will have approximately $737 million in cash and securities, supporting multiple clinical trial readouts and operations into 2027.
– Alumis will retain its name and leadership team, with an expanded board including two ACELYRIN members, and the merger is expected to close in Q2 2025.

Alumis Inc. (NASDAQ: ALMS) and ACELYRIN (NASDAQ: SLRN) have announced a definitive merger agreement, combining the two clinical-stage biopharmaceutical companies in an all-stock transaction aimed at advancing immunology treatments and optimizing clinical outcomes.

Strategic Rationale and Financial Position

The merger will create a strongly capitalized company with a combined cash, cash equivalents, and marketable securities position of approximately $737 million as of year-end 2024. This financial strength is expected to support the advancement of the companies’ combined pipeline through multiple key clinical data readouts and fund operating expenses and capital expenditures into 2027.

The combined company will leverage its track record in research and development and a proprietary data and analytics platform to drive innovation in immune-mediated diseases.

Martin Babler, President, CEO, and Chairman of Alumis, stated: “Through this combination with ACELYRIN, Alumis will have the financial flexibility and runway to advance an expanded late-stage pipeline, now including lonigutamab, and build commercial capabilities. Since completing our IPO, Alumis has operated with speed and rigor, and the multiple development milestones expected in 2025 and 2026, coupled with potential additional indications for ESK-001, represent exciting breakthroughs for our patients and value-driving opportunities for the combined company’s stockholders. As we move forward together, we will maintain financial discipline and a flexible capital allocation strategy with the goal of maximizing the value of our highly differentiated portfolio.”

Pipeline Highlights

  • Alumis’ ESK-001: A next-generation, allosteric TYK2 inhibitor, currently in Phase 3 ONWARD trials for moderate-to-severe plaque psoriasis (PsO) and Phase 2b LUMUS trials for systemic lupus erythematosus (SLE). Key Phase 2 52-week updates expected in 2025, with Phase 3 topline data in H1 2026.
  • Alumis’ A-005: A CNS-penetrant allosteric TYK2 inhibitor, targeting neuroinflammatory and neurodegenerative diseases like multiple sclerosis (MS) and Parkinson’s Disease. A Phase 2 trial is set to begin in H2 2025.
  • ACELYRIN’s Lonigutamab: A subcutaneous anti-IGF-1R therapy with best-in-class potential for thyroid eye disease (TED), currently under Phase 2 evaluation.

Transaction Terms & Leadership Structure

  • Exchange Ratio: ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each ACELYRIN share owned.
  • Ownership Breakdown: 55% Alumis stockholders, 45% ACELYRIN stockholders post-transaction.
  • Leadership: The combined company will operate under the Alumis name and be led by Alumis’ executive team, strengthened by key ACELYRIN professionals and medical experts.
  • Board Expansion: The board will grow to nine members, including two from ACELYRIN.
  • Closing Timeline: The transaction is expected to close in Q2 2025, subject to regulatory and shareholder approvals.

This merger brings together two companies dedicated to transforming immunology treatments, strengthening their pipeline, and delivering long-term value to patients and investors alike.

January Jobs Report Shows Slower-Than-Expected Growth

Key Points:
– January job growth slowed to 143,000, falling below expectations and marking a sharp decline from December’s revised 307,000 gain.
– Wage growth increased by 4.1% over the past year, outpacing inflation but continuing to pose affordability challenges for consumers.
– The Federal Reserve and markets are closely monitoring labor trends, while rising trade policy uncertainty and potential economic shifts under President Trump add to financial volatility.

The U.S. labor market saw weaker-than-expected job growth in January, with nonfarm payrolls increasing by 143,000, below the Dow Jones forecast of 169,000 and down from a revised 307,000 in December. Meanwhile, the unemployment rate declined to 4.0%, showing continued resilience in the job market despite the slowdown in hiring.

Key Takeaways from the January Jobs Report

  • Weaker Job Growth: January’s 143,000 job gain marks a sharp decline from December and falls below expectations.
  • Downward Revisions: Total payroll numbers for 2024 were revised downward by 589,000 over the trailing 12-month period ending in March 2024.
  • Sector Performance:
    • Healthcare: +44,000 jobs
    • Retail: +34,000 jobs
    • Government: +32,000 jobs
  • Labor Force Participation: Increased 0.1% from December to 62.6%.
  • 2024 Job Growth Trend: The monthly average for job growth in 2024 stood at 166,000 per month.
  • Wage Growth: Average hourly earnings rose 4.1% over the past year, partly due to minimum wage hikes in parts of the country.
  • Affordability Challenges: Wage growth continues to outpace recent inflation rates, but many consumers still face affordability challenges.

Market and Federal Reserve Reactions

Markets showed little reaction to the report in early trading, as investors had largely anticipated a slowdown in job creation. Federal Reserve officials are closely monitoring labor market data as they consider future monetary policy moves. The Fed cut its benchmark interest rate by a full percentage point in late 2024, and today’s report may influence their next steps regarding interest rate adjustments. President Trump recently stated that the Fed’s decision last week to hold rates steady was well-advised, despite previously criticizing the move.

Broader Economic and Political Context

Some indicators, such as hiring rates, suggest slower movement in the job market. Meanwhile, business executives remain optimistic that Trump’s policies—such as tax cuts and deregulation—will boost economic growth. However, Trump’s recent tariff decisions have rattled markets, adding to economic uncertainty. Rising trade policy uncertainty could further heighten financial market volatility in the coming months.

The Historical Importance of Jobs Reports

The monthly jobs report is one of the most closely watched economic indicators, providing insights into labor market health, consumer spending power, and broader economic momentum. Historically, strong job growth has been associated with economic expansion, while sluggish reports can indicate slowdowns or even recessions. Policymakers, investors, and businesses use these reports to make critical decisions on interest rates, hiring strategies, and economic forecasts. In the current environment, sustained job growth and wage pressures suggest a resilient labor market, even as broader economic uncertainties loom.

With job growth slowing but unemployment remaining stable, policymakers will weigh the need for further economic stimulus against concerns of overheating the labor market. The upcoming months will be crucial in determining whether this slowdown is temporary or indicative of a broader labor market trend.

TPG to Acquire Altus Power in $2.2 Billion Deal

Key Points:
– TPG Rise Climate will acquire Altus Power for $5.00 per share in a $2.2 billion deal, taking the company private to accelerate clean energy expansion.
– Altus Power’s Board of Directors unanimously approved the transaction, which represents a 66% premium to its October 2024 stock price and is expected to close in Q2 2025.
– This acquisition aligns with TPG Rise Climate’s strategy to scale climate solutions, leveraging its expertise in clean energy infrastructure to support Altus Power’s growth.

Altus Power, the largest owner of commercial-scale solar in the U.S., has announced that it has entered into a definitive agreement to be acquired by TPG through its TPG Rise Climate Transition Infrastructure strategy. Under the terms of the agreement, TPG will acquire Altus at $5.00 per share, valuing the company at approximately $2.2 billion, including outstanding debt. Upon completion of the transaction, Altus Power will become a privately held company.

Strategic Rationale and Market Impact

On October 15, 2024, Altus Power initiated a formal review of strategic alternatives. Today’s purchase price represents a 66% premium to Altus’ closing price on that date. The company expects this acquisition to bolster its ability to provide greater value to both commercial and Community Solar customers while expanding access to clean electric power.

“This transaction represents a pivotal moment for Altus Power,” said Gregg Felton, CEO of Altus Power. “We are incredibly excited to partner with TPG Rise Climate to continue to build our position as the leading commercial-scale provider of clean electric power to businesses and households from coast to coast. TPG Rise Climate’s deep expertise in the clean energy sector, investment-oriented mindset, and value-driven approach to infrastructure development align perfectly with our vision. This partnership strengthens our ability to serve both our Community Solar and commercial clients with clean electric power at a time when demand for power is expected to grow substantially. As a private company, Altus Power will be better positioned for continued long-term growth, which we believe will allow us to scale our operations, drive innovation, and enhance the value we deliver to our customers. Together with TPG Rise Climate, we believe we are poised to accelerate clean energy adoption and ensure more businesses and communities have access to the power they need for a sustainable future.”

Transaction Details

  • The Board of Directors of Altus has unanimously approved the transaction and recommends that Altus stockholders vote to adopt the merger agreement.
  • The deal is contingent upon majority approval by Class A stockholders.
  • The transaction is expected to close in Q2 2025.

About TPG Rise Climate

TPG Rise Climate is the dedicated climate investing platform of TPG, a leading global alternative asset management firm. With dedicated pools of capital across private equity, transition infrastructure, and the Global South, TPG Rise Climate focuses on climate-related investments that benefit from the expertise of TPG’s investment professionals and its global network of executives, advisors, and corporate partners. As part of TPG’s $25 billion global impact investing platform, TPG Rise Climate invests broadly in the climate sector, emphasizing clean electrons, clean molecules and materials, and negative emissions.

About Altus Power

Altus Power is a leader in commercial-scale solar energy, providing clean, renewable energy solutions for businesses and communities across the U.S. The company is currently traded on the New York Stock Exchange under the ticker symbol AMPS.

Above Food to Acquire Palm Global Technologies, Expanding into Agri-Tech and Sustainable Innovation

Key Points:
– Above Food Ingredients Inc. (NASDAQ: ABVE) has signed a Letter of Intent to acquire Palm Global Technologies Ltd. in a $180 million share exchange, expanding into Agri-Tech, FinTech, and carbon credit securitization.
– Palm Global’s proprietary AI, blockchain, and decentralized finance technologies will enhance Above Food’s vertically integrated food systems, supporting sustainable agriculture and economic empowerment for millions of farmers.
– Following the acquisition, Palm Global’s Peter Knez will become Chairman and CEO of the combined companies, with definitive agreements expected to be finalized and closed in the near term.

Above Food Ingredients Inc. (NASDAQ: ABVE), a leader in sustainable, vertically integrated food systems, has signed a Letter of Intent (LOI) to acquire Palm Global Technologies Ltd., a next-generation innovator in technology, sustainability, and global food markets. The acquisition is expected to strengthen Above Food’s position in Agri-Tech, FinTech, and carbon credit securitization, further advancing its commitment to sustainable food production and innovation.

Strategic Rationale and Industry Impact

The transaction will integrate Above Food’s vertically integrated food systems with Palm Global’s groundbreaking technologies, alliances, and global reach. Palm Global’s proprietary AI, blockchain, and decentralized finance technologies are designed to drive economic empowerment, education, and sustainable growth, particularly in underserved markets, benefiting tens of millions of farmers worldwide.

“This transformative acquisition positions Above Food to redefine global agriculture and sustainability while unlocking a number of significant opportunities in high-growth markets,” said Lionel Kambeitz, Founder and CEO of Above Food. “Palm Global’s innovative technologies, combined with its mission to drive economic empowerment, align perfectly with our vision for sustainable food solutions worldwide.”

Palm Global’s Technological and Strategic Contributions

  • AI, Blockchain, and DeFi Technologies – Palm Global’s solutions enhance efficiency, security, and accessibility in the global food supply chain.
  • Partnerships with Governments and Institutions – Palm Global collaborates with entities like the Peace for Life Foundation, IIMSAM, and global institutions to accelerate technology adoption among farmers.
  • Strategic Global Alliances – The acquisition allows Above Food to leverage Palm Global’s extensive partnerships to develop, utilize, and maximize R&D capabilities in agronomy and genomics.

The newly combined entity will enable innovative initiatives such as regenerative agriculture and grow-to-order food solutions, creating customized approaches to meet evolving consumer and agricultural needs.

Transaction Details and Leadership Transition

  • The LOI outlines a share exchange valuing Palm Global at approximately $180 million.
  • Definitive agreements are expected this month, with approvals and closing anticipated soon after.
  • Peter Knez, currently on Palm Global’s Board of Directors, will assume the role of Chairman and CEO of the combined companies.

Future Outlook

This merger is set to enhance global food security, promote sustainable agriculture, and create economic opportunities in underserved markets through technological innovation and strategic partnerships. By combining resources, Above Food and Palm Global aim to drive the next wave of transformation in sustainable food production and agricultural technology.

Teladoc Health to Acquire Catapult Health, Expanding Preventive and At-Home Care Offerings

Key Points:
– Teladoc Health is acquiring Catapult Health for $65 million to enhance its preventive care and at-home diagnostic testing capabilities, further strengthening its integrated healthcare solutions.
– Catapult Health’s VirtualCheckup program will enable Teladoc to expand its chronic condition management services and seamlessly connect high-risk patients to virtual care programs.
– This acquisition comes as Teladoc seeks to regain momentum following its 2020 Livongo acquisition, which initially valued the combined company at $37 billion but has since declined to a market cap under $2 billion.

Teladoc Health has announced a definitive agreement to acquire Catapult Health, a move aimed at strengthening its preventive care and chronic condition management capabilities while expanding its at-home diagnostic testing offerings. This acquisition aligns with Teladoc’s strategy to enhance virtual care accessibility and effectiveness for its over 93 million members.

Catapult Health is recognized for its innovative approach to at-home wellness and diagnostic testing, which integrates virtual clinical support and high-touch patient engagement. Teladoc plans to leverage these capabilities to further enrich its industry-leading suite of integrated healthcare solutions.

“This acquisition will help advance our strategy in meaningful ways — from giving more members access to convenient and impactful wellness and preventive care, to unlocking greater value for our customers,” said Chuck Divita, Chief Executive Officer of Teladoc Health. “Catapult Health brings an experienced team and a strong culture of innovation, and we are thrilled to welcome them to Teladoc Health.”

Strategic Objectives and Synergies

Teladoc Health’s integrated care strategy is built on four key pillars:

  • Expanding Membership and Service Utilization – Enhancing the accessibility and engagement of healthcare services for existing and new members.
  • Leveraging Clinical Expertise and Product Breadth – Strengthening healthcare outcomes by integrating a broader range of clinical solutions.
  • Growing International Presence – Extending Teladoc’s reach beyond domestic markets to serve a global population.
  • Advancing Mental Health Solutions – Building upon its existing leadership in virtual mental health services.

Catapult Health’s flagship VirtualCheckup program exemplifies its innovation in preventive care. The at-home wellness exam provides members with a simple diagnostic kit, allowing them to collect blood samples, measure blood pressure, and submit other key health data. Following this, a virtual consultation with a licensed healthcare professional ensures timely assessment and guidance.

For members identified with high-risk factors or chronic conditions, Catapult’s clinicians can seamlessly enroll them into Teladoc’s condition management programs, including diabetes, hypertension, pre-diabetes, and weight management. Additionally, members can be referred to Teladoc’s virtual mental health specialists and primary care providers for continued support.

Transaction Details

The acquisition is structured as an all-cash transaction valued at $65 million, with up to $5 million in contingent earnout consideration. Catapult Health reported $30 million in trailing 12-month revenue as of Q3 2024. Upon closing, Catapult will be integrated into Teladoc’s Integrated Care segment. The deal is expected to close in Q1 2025.

Impact and Market Expansion

Catapult Health currently serves over 3 million people through its partnerships with hundreds of employer clients. The company is recognized for its strong customer satisfaction, clinical outcomes, and cost-saving benefits, including an estimated $1,400 average savings per participant over a three-year period due to early disease detection and health risk identification.

Teladoc’s Market Challenges and Context

This acquisition comes after a tumultuous period for Teladoc. Following its acquisition of Livongo in 2020, the combined companies had an enterprise value of $37 billion. However, Teladoc’s stock has struggled since then, with a current market capitalization just under $2 billion. The acquisition of Catapult Health represents a strategic effort to regain momentum and strengthen its position in the evolving telehealth market.

U.S. Trade Deficit Hits Second-Highest Annual Total in 2024; December Deficit Sets Record

Key Points:
– The U.S. trade deficit reached $918.4 billion in 2024, marking the second-largest annual total, while December’s deficit set a record at $98.4 billion.
– Strong consumer demand, a robust U.S. dollar, and rising imports—particularly in industrial supplies and consumer goods—outpaced export growth, widening the trade gap.
– Escalating trade tensions, including newly imposed and proposed tariffs on Mexico, Canada, and China, could further disrupt trade flows and market stability in 2025.

The U.S. trade deficit surged to $918.4 billion in 2024, marking the second-highest annual total in history. This 17% increase from 2023 was driven primarily by a sharp rise in imports, which climbed 6.6% to $4.11 trillion, outpacing export growth of 3.9% to $3.19 trillion.

According to the U.S. Census Bureau and the Bureau of Economic Analysis, December’s trade deficit reached a record-high $98.4 billion, up $19.5 billion from November. Monthly exports dropped to $266.5 billion, while imports surged to $364.9 billion.

Key Trends in 2024 Trade Data

  • Record Merchandise Trade: The U.S. set all-time highs for total merchandise trade, imports, and the December monthly trade deficit.
  • Regional Trade Concentration: Nearly 41% of total U.S. trade involved Mexico, Canada, and China.
  • Strong Consumer Demand: Americans continued spending on imported goods such as weight-loss drugs, auto parts, computers, and food, supported by a strong U.S. dollar that made foreign products more affordable.
  • Declining Vehicle Exports: U.S. auto-related exports fell by $10.8 billion, largely due to intensified competition from China’s expanding auto industry.
  • Growth in Services Sector: Foreign spending on U.S. travel, business, and financial services helped boost service sector exports, which reached $1.107 trillion, up $81.2 billion from 2023.

Policy and Market Impact

Trade flows could face further disruption in 2025 as President Trump escalates trade tensions. This week, the administration imposed—then temporarily paused—25% tariffs on imports from Mexico and Canada. Trump has also proposed an additional 10% tariff on all Chinese imports, building on existing 25% duties from his first term. In response, China announced $20 billion in retaliatory tariffs and new export restrictions on critical minerals.

The U.S. posted its largest bilateral trade deficit with China at $295.4 billion, while also running record deficits with Mexico, Vietnam, India, Taiwan, South Korea, and the European Union. Meanwhile, Trump has made reducing the trade deficit “to zero” a primary policy objective and is considering imposing tariffs on the EU and UK.

Economic Context

A strong U.S. economy and a robust dollar fueled demand for imports, even as American exports faced headwinds in global markets. The U.S. trade deficit as a share of GDP rose to 3.1% in 2024, up from 2.8% in 2023. Many essential goods, such as consumer products and apparel, are no longer produced domestically, further reinforcing America’s reliance on imports.

As businesses rushed to import goods ahead of potential tariff hikes, the trade deficit soared in December, setting a record for the highest monthly deficit and contributing to the second-largest annual trade gap in U.S. history. With ongoing trade disputes and policy shifts, global trade flows could remain volatile in the months ahead.

Lifeway Foods (LWAY) – Danone Ups Offer to $27


Friday, November 15, 2024

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Ups Offer. In an amended Schedule 13D filing on Friday morning, Danone upped their offer to acquire the shares of Lifeway not already owned to $27, all cash, from a prior $25. According to a letter filed with the amended 13D, Danone believes the “updated indicative price fully reflects the fundamental potential of the Company and provides Lifeway’s shareholders with the certainty of an attractive and immediate cash premium.”

3 Week Timing. Although Danone has yet to be granted access to any due diligence, Danone is prepared to conduct due diligence as soon as provided access to a data room. Danone also is ready to enter into immediate negotiations regarding the terms of a potential transaction. Subject to Danone being able to access immediately the information required as part of confirmatory due diligence and negotiating Transaction Documentation in parallel, Danone is confident in its ability to reach a definitive agreement in three weeks.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GDEV Inc (GDEV) – Nearly Doubles Street Expectations


Friday, November 15, 2024

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Over delivered on Q3 results. Total company revenue was $110.7 million, beating our $103.0 million estimate. With costs in line with expectations, the revenue upside flowed to adj. EBITDA, which substantially exceeded our expectations, of $16.9 million versus our estimate of $4.9 million, as illustrated in Figure #1 Q3 Results. We believe that the results beat Street estimates, with consensus adj. EBITDA of $8.5 million.

Upside variance. The company is seeking ways to make efficient use of its marketing spend, particularly in areas that provide sufficient returns. Sales & Marketing expenses of $52.0 million were lower than our $53.0 million estimate in spite of better than expected revenues. We anticipate Sales & Marketing expenses to accelerate in coming quarters as the company hones in on its marketing strategy and expands into new territories. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The NobleCon20 VIP Giveaway

Noble Financial Group and Channelchek are pleased to present the NobleCon20 VIP Giveaway. This contest was open exclusively to registered, verified Channelchek members.

Contest is now closed.  The winner will be announced on November 18, 2024. The winner was notified via email on November 15.

Learn more about NobleCon20 @ www.nobleconference.com

Three Biotech Companies Price Their IPOs, Raising Significant Capital for Future Growth

Key Points:
– Upstream Bio raised $255 million to fund advanced trials for its respiratory disease drug verekitug, achieving a valuation of $830 million.
– Ceribell raised $180 million to further develop its AI-powered EEG platform, focusing on diagnosing serious neurological conditions.
– CAMP4 Therapeutics raised $75 million to continue its work in gene expression therapies, pricing its IPO below expectations at $11 per share.

Three biotech companies priced their initial public offerings (IPOs) on Thursday, securing substantial funding to advance their innovative therapies and technologies. The companies—Upstream Bio, Ceribell, and CAMP4 Therapeutics—collectively raised millions, with plans to use the proceeds for various clinical trials and product developments.

Upstream Bio: Raising $255 Million for Respiratory Therapies Upstream Bio led the day by raising $255 million, with its shares priced at the higher end of the expected range. Initially planning to sell 12.5 million shares between $15 and $17 each, the company increased the offering to 15 million shares due to high demand, pricing them near $17. This could further rise if underwriters exercise their option to purchase an additional 2.25 million shares. The company, which now has a valuation of around $830 million, will trade on the NASDAQ under the ticker symbol UPB.

Upstream Bio is using the capital to advance clinical trials for its lead drug, verekitug, which is being tested for severe asthma and chronic rhinosinusitis with nasal polyps. The drug targets a receptor for thymic stromal lymphopoietin, a key player in inflammatory diseases. Proceeds will also help initiate a phase 3 trial for severe asthma.

Ceribell: Secures $180 Million for AI-Powered Neurological Diagnostics Ceribell, a commercial-stage medical technology company, raised $180 million through its IPO, with 10.6 million shares priced at $17 each, giving the company a valuation of $578 million. Like Upstream, Ceribell also granted underwriters the option to purchase additional shares—up to 1.6 million more. The company will trade on the NASDAQ under the symbol CBLL.

Ceribell specializes in AI-powered neurological diagnostic tools, notably its point-of-care electroencephalography (EEG) platform, designed to help in the diagnosis and management of critical neurological conditions. The technology is expected to revolutionize the way healthcare providers address neurological emergencies.

CAMP4 Therapeutics: Raises $75 Million Despite Pricing Below Expectations CAMP4 Therapeutics saw its IPO priced below expectations, at $11 per share, compared to an initial range of $14 to $16. Despite this, the company managed to sell 6.8 million shares, surpassing its original goal of 5 million, for total gross proceeds of $75 million. CAMP4 will begin trading on the NASDAQ under the ticker symbol CAMP.

CAMP4 focuses on regulatory RNA-targeting therapeutics, aiming to upregulate gene expression in genetic diseases. The proceeds will be used to further develop its drug pipeline, including its recent collaboration with BioMarin to target RNA sequences for therapeutic applications.

TD Bank to Pay $3 Billion in Landmark Money Laundering Settlement

Key Points:
– TD Bank has agreed to a $3 billion settlement with the DOJ after pleading guilty to conspiracy to commit money laundering, the largest such plea by a U.S. bank.
– The bank allowed $670 million in laundered funds to flow through its accounts over multiple years due to lapses in its anti-money laundering program.
– TD is undergoing major reforms, with federal monitoring and restrictions in place, alongside additional penalties from the Federal Reserve Board and CFPB.

TD Bank has agreed to a $3 billion settlement with the U.S. Department of Justice (DOJ) after pleading guilty to conspiracy to commit money laundering, marking the largest such plea from a U.S. bank in history. The charges stem from TD’s failure to adequately address issues in its anti-money laundering program over multiple years, allowing significant illegal financial activity to take place. The Canadian-based bank, the 10th largest in the U.S., has committed to a series of reforms as part of the settlement, including a complete restructuring of its compliance operations.

Major Failures in Anti-Money Laundering Program

According to U.S. officials, TD Bank allowed $670 million in laundered funds to pass through its accounts from three separate networks. One case involved a single individual moving over $470 million in drug-related and other illegal proceeds. Another involved TD employees allegedly collaborating with criminal organizations to launder $39 million to Colombia. These significant failures in TD’s oversight system included transactions exceeding daily limits by over 50 times, without proper scrutiny.

Attorney General Merrick Garland emphasized that TD executives were warned of these issues but did not take corrective action in time. As a result, TD will undergo three years of federal monitoring and five years of probation to ensure the bank’s compliance improvements.

Reforms and Response from TD Bank

TD’s CEO Bharat Masrani expressed regret, stating that the bank accepts full responsibility for the lapses and is committed to fixing its anti-money laundering program. As part of its remediation efforts, TD has appointed new leadership and hired hundreds of specialists to address the compliance shortfalls. The bank has also admitted to failing to monitor $18.3 trillion in customer transactions over six years.

In addition to the settlement, the Federal Reserve Board imposed $124 million in fines earlier this week for violations related to anti-money laundering regulations. The Office of the Comptroller of the Currency (OCC) will restrict TD’s growth until further notice, and the Financial Crimes Enforcement Network (FinCEN) has imposed a four-year independent monitorship to oversee the bank’s efforts to prevent future violations.

Further Legal Consequences

Beyond corporate penalties, two TD employees have been prosecuted, along with two dozen other individuals involved in the laundering schemes. More prosecutions are expected as investigations continue. TD’s legal troubles extend beyond this case, as the Consumer Financial Protection Bureau (CFPB) recently fined the bank $28 million for providing inaccurate customer information to reporting agencies and failing to address these errors.